Clinical trial
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
NCT00005845 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005845 |
|---|---|
| Title | Tipifarnib in Treating Patients With Myelodysplastic Syndromes |
| Official title | Phase I Study of the Farnesyl Transferase Inhibitor R115777 (NSC #702818) in Patients With Myelodysplastic Syndrome |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia |
| Intervention type | Drug, Other |
| Interventions | tipifarnib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 65 |
| Start date | Jun 1, 2002 |
| Primary completion | Sep 1, 2009 |
| First posted | Aug 29, 2003 |
| Last update posted | Dec 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: